“This is a study of hope and optimism,” said Michael Alosco, co-senior author of the latest paper and co-director of clinical research at the BU CTE Center. “This is a study that really brings us closer to being able to diagnose across the lifespan, and that’s what we’ve been working on for so many years now.”
The results are still preliminary, and there are no approved blood tests for CTE. But the findings mark a much-anticipated step toward better understanding the disease, which is likely caused by repeated head injuries, including concussions and milder impacts. Because CTE can only be definitively diagnosed after death through analysis of brain tissue, its true impact on living people remains unclear. This has made it difficult to develop treatments and prevention strategies.
The threat CTE poses to football players has recently become more visible. A study released in October estimated that nearly three-quarters of all NFL players who died during a recent 15-year period suffered from CTE. Athletes who play other contact sports, including hockey, rugby and football, may also be at risk. The disease has also been detected in the brains of military personnel.
Symptoms most often include cognitive impairment and dementia, as well as changes in behavior and mood, which can be serious. Not all players with CTE will develop symptoms, especially in the early stages of the disease.

The new research examined 21 soccer players, including former professional, collegiate and high school athletes, who gave blood samples while alive and donated their brains after death. Of the players studied, 18 had confirmed CTE and most were diagnosed with advanced disease.
Using the last blood samples taken before the players died, the researchers looked for a protein in the blood that could be a marker for tau tangles in the brain that are found in both CTE and Alzheimer’s patients, Alosco said. Tangles form inside neurons and can damage or even kill them.
The study found that athletes with more advanced disease had higher protein concentrations than those in earlier stages and people who did not have CTE.
“What was really striking was the difference,” Alosco said. “The high-stage CTE concentrations were much higher than in anyone else, and that really stood out.”
The BU researchers led the study with colleagues at Banner Health, a hospital system in Arizona.
Highest levels of protein have been found in people with both CTE and Alzheimer’s disease. But the researchers also studied another protein associated with Alzheimer’s disease and found that it was not linked to CTE. These combined results suggest that the two biomarkers could be used to detect CTE and differentiate it from Alzheimer’s disease, a condition similar to traumatic brain injury, Alosco said.
But he and other experts stressed that the research was still in its “discovery phase.”
The protein identified in the study is exciting for the field, said Dr. Ramon Diaz-Arrastia, a professor of neurology at the University of Pennsylvania Perelman School of Medicine, who was not involved in the research. But he said the study’s sample size was small and the analysis left some crucial questions unanswered.
“It’s really just a clue,” Diaz-Arrastia said. “The sample size was way too small for us to make any guesses and estimates about diagnostic thresholds and that sort of thing.”
Derek Monroe, assistant professor of exercise and sports sciences at UNC Chapel Hill, said the study participants are also not representative of the broader population or even all football players. The analysis also included very few people with early-stage CTE or no disease.
“Before we know how this test works, it needs to be studied in a broader group of people: those with and without a history of head impacts, with and without symptoms, followed over time,” said Monroe, who was not involved in the study.
He and other experts noted that diagnosing CTE in the future would likely require more than one test, including brain imaging.
“Ultimately, I don’t think one marker can solve this problem,” Monroe said. “The most realistic path is a combination of tools.”
Although the paper’s authors acknowledge the limited sample size, they pointed to a recent study by scientists at Washington University in St. Louis, who used a different approach and found that a related protein was higher in people with advanced CTE.
“It is very encouraging that two independent groups with two independent methods came to the same conclusion,” said Chihiro Sato, assistant professor of neurology at Washington University in St. Louis and co-correspondent and lead author of the other study, also published in JAMA.
Alosco said researchers are well-positioned to continue studying the latest findings. According to him, more and more people are participating in studies and donating their brains.
“In the not-so-distant future, we will be able to do a larger study of this type to validate it on a larger sample,” he said. “If the results hold up to future studies, this will really change the landscape.”
Richard McElroy’s family said they wish the former college athlete, who was one of the players included in the BU study, could have been diagnosed sooner.


Janice Howard McElroy said her husband’s behavior began to change in his early 50s. Richard McElroy, who rarely got angry, began having sudden outbursts and drinking heavily. At first, his wife thought he was going through a mid-life crisis.
“I didn’t know what was happening,” she said. “He had the most generous and loving heart.”
Richard McElroy, who played football for four years at Mississippi State University, received care from BU’s CTE experts. When he died in January at the age of 74, one of the first things his family did was begin arranging for his brain to be donated. This allowed McElroy, who was ultimately diagnosed with stage 4 CTE, to be included in the study.
“I obviously wish it would have helped him, but it still makes us unbelievable that this could be his legacy,” said his daughter Kristina McElroy, who spoke through tears. “He helps others.”
Allyson Chiu can be contacted at allyson.chiu@globe.com. Follow her on @_allysonchiu.
Gn Health
